Literature DB >> 7757983

Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

D M Bollag1, P A McQueney, J Zhu, O Hensens, L Koupal, J Liesch, M Goetz, E Lazarides, C M Woods.   

Abstract

Tubulin polymerization into microtubules is a dynamic process, with the equilibrium between growth and shrinkage being essential for many cellular processes. The antineoplastic agent taxol hyperstabilizes polymerized microtubules, leading to mitotic arrest and cytotoxicity in proliferating cells. Using a sensitive filtration-calorimetric assay to detect microtubule nucleating activity, we have identified epothilones A and B as compounds that possess all the biological effects of taxol both in vitro and in cultured cells. The epothilones are equipotent and exhibit kinetics similar to taxol in inducing tubulin polymerization into microtubules in vitro (filtration, light scattering, sedimentation, and electron microscopy) and in producing enhanced microtubule stability and bundling in cultured cells. Furthermore, these 16-membered macrolides are competitive inhibitors of [3H]taxol binding, exhibiting a 50% inhibitory concentration almost identical to that of taxol in displacement competition assays. Epothilones also cause cell cycle arrest at the G2-M transition leading to cytotoxicity, similar to taxol. In contrast to taxol, epothilones retain a much greater toxicity against P-glycoprotein-expressing multiple drug resistant cells. Epothilones, therefore, represent a novel structural class of compounds, the first to be described since the original discovery of taxol, which not only mimic the biological effects of taxol but also appear to bind to the same microtubule-binding site as taxol.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7757983

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  225 in total

Review 1.  Tubulin interacting agents: novel taxanes and epothilones.

Authors:  Neeraj R Agrawal; Ram Ganapathi; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

2.  Cyclostreptin derivatives specifically target cellular tubulin and further map the paclitaxel site.

Authors:  Enrique Calvo; Isabel Barasoain; Ruth Matesanz; Benet Pera; Emilio Camafeita; Oriol Pineda; Ernest Hamel; Christopher D Vanderwal; José Manuel Andreu; Juan A López; José Fernando Díaz
Journal:  Biochemistry       Date:  2011-12-30       Impact factor: 3.162

3.  The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice.

Authors:  T C Chou; O A O'Connor; W P Tong; Y Guan; Z G Zhang; S J Stachel; C Lee; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 4.  Mechanisms of Taxol resistance related to microtubules.

Authors:  George A Orr; Pascal Verdier-Pinard; Hayley McDaid; Susan Band Horwitz
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

5.  Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton.

Authors:  A Dietzmann; D Kanakis; E Kirches; S Kropf; C Mawrin; K Dietzmann
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

Review 6.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

7.  A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Linda R Duska; John A Blessing; Jacob Rotmensch; Robert S Mannel; Parviz Hanjani; Peter G Rose; Don S Dizon
Journal:  Gynecol Oncol       Date:  2014-08-01       Impact factor: 5.482

8.  A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.

Authors:  J A Ajani; H Safran; C Bokemeyer; M A Shah; H-J Lenz; E Van Cutsem; H A Burris; D Lebwohl; B Mullaney
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

9.  Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.

Authors:  Brigitte C Widemann; Wendy Goodspeed; Anne Goodwin; Tito Fojo; Frank M Balis; Elizabeth Fox
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

Review 10.  Targeting microtubules by natural agents for cancer therapy.

Authors:  Eiman Mukhtar; Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.